Hadassah

Collaboration Announced to Develop Hadassah Drug to Treat “Untreatable” NASH Liver Disease

Friday, Aug 5 2016

Hadasit, the Hadassah Medical Organization’s technology transfer company, has signed an agreement with BioLineRx Ltd. to develop a drug to treat non-alcoholic steatohepatitis (NASH), based on the pre-clinical work of Hadassah’s Prof. Rifaat Safadi, head of its Liver Unit. Currently, there are no Federal Drug Administration-approved treatments for NASH.

NASH is the progressive form of non-alcoholic fatty liver disease (NAFLD) and, in many cases, leads to cirrhosis of the liver and, ultimately, liver cancer. This “in-licensing agreement” represents a partnership between two companies with shared intentions, goals, and fields of interest. "Under the collaboration,” explains Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx,” Novartis will provide us with valuable professional advice and consultancy throughout the development process. This project fits our strategic focus on the immunology space, since it works through modulation of the immune system.”

The drug candidate, to be called BL-1210, offers a novel mechanism for controlling liver fibrosis, the scarring process that represents the liver's response to injury. When scar tissue builds up and takes over most of the liver, cirrhosis is the result. By modulating the immune system, the drug would reduce scarring and control the disease’s progression.

As Hadasit explains about the Hadassah Medical Center on its website, “The combination of practical experience, the ability to pinpoint medical needs, and cutting-edge research has yielded a huge potential for ideas, innovation, and developments in all aspects of medicine, including therapeutics, diagnostics, and medical devices. Founded in 1986, Hadasit has been investing in turning ideas into viable products and services for the benefit of humanity.”

Comments

From: Michelle on August 25, 2016
I was first diagnosed with NASH in 2003. Nobody I knew had ever heard of NASH. At the beginning even some of my doctors, often were unknowldgeable on NASH. I was their key to unlock the information vault. I am willing to be a test subject.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Monday, Dec 10 2018

A Nurses Council Celebration in Israel: The Milestone Mission

We were honored to meet so many dynamic Hadassah nurses, some longtime and some new members--all of us excited to be together to celebrate the 100th anniversaries of the Hadassah Medical Organization, the Henrietta Szold Hadasssah-Hebrew University Nursing School and HMO's Department of Ophthalmology. And Israel's 70th

READ MORE ›
alt_text

Wednesday, Dec 5 2018

Prof. Chowers’ Long and Meaningful Hadassah Connections

Sophie Szold, mother of Hadassah founder Henrietta, wept when she saw children with flies in their eyes on their maiden trip to pre-state Israel in 1909. Those children had trachoma, endemic in the Middle East in those days.

READ MORE ›
alt_text

Wednesday, Dec 5 2018

Ending the Violence Against Women: Hadassah Staff Joins Nationwide Protests

On December 4, employees from both Hadassah Hospital Ein Kerem and Hadassah Hospital Mount Scopus rallied to end violence against women. “Together we will banish the darkness and return the light to all women,” read banners held by the participants.

READ MORE ›
alt_text

Tuesday, Dec 4 2018

No Ovaries? Mystery Solved By Hadassah Endocrinologist

A few years ago, a mother brought her teenage daughter to see Prof. David Zangen, Director of Pediatric Endocrinology at the Hadassah Medical Organization.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More